tiprankstipranks
BiVictriX Therapeutics PLC (GB:BVX)
LSE:BVX
Holding GB:BVX?
Track your performance easily

BiVictriX Therapeutics PLC (BVX) Income Statement

0 Followers

BiVictriX Therapeutics PLC Income Statement

Last quarter (Q4 2022), BiVictriX Therapeutics PLC's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, BiVictriX Therapeutics PLC's net income was £―. See BiVictriX Therapeutics PLC’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---£ 0.00£ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
-£ 2.98M£ 1.50M£ 521.00K£ 526.00K
Operating Income
-£ -2.98M£ -1.50M£ -521.00K£ -526.00K
Net Non Operating Interest Income Expense
-£ 4.00K£ 641.00K£ -19.00K-
Other Income Expense
-----
Pretax Income
-£ -2.97M£ -2.53M£ -509.00K£ -526.00K
Tax Provision
-£ -474.00K£ -192.00K£ -84.00K£ -117.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-£ -2.50M£ -2.34M£ -425.00K£ -409.00K
Basic EPS
-£ -0.04£ -0.06£ >-0.01£ >-0.01
Diluted EPS
-£ -0.04£ -0.06£ >-0.01£ >-0.01
Basic Average Shares
-£ 66.12M£ 38.87M£ 66.12M£ 66.12M
Diluted Average Shares
-£ 66.12M£ 38.87M£ 66.12M£ 66.12M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
---£ 18.00K£ 17.00K
Total Expenses
-£ 2.98M£ -1.50M£ 521.00K£ 526.00K
Net Income From Continuing And Discontinued Operation
-£ -2.50M£ -2.34M£ -425.00K£ -409.00K
Normalized Income
-£ -3.44M£ -2.33M£ -450.88K£ -409.00K
Interest Expense
---£ 19.00K-
EBIT
-£ -2.97M£ -1.89M£ -490.00K£ -526.00K
EBITDA
-£ -2.82M£ -1.89M£ -489.00K£ -526.00K
Currency in GBP

BiVictriX Therapeutics PLC Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis